Trials / Completed
CompletedNCT03419897
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Administered intravenously |
Timeline
- Start date
- 2018-04-09
- Primary completion
- 2021-06-30
- Completion
- 2022-07-06
- First posted
- 2018-02-05
- Last updated
- 2024-10-26
- Results posted
- 2023-07-27
Locations
54 sites across 8 countries: China, France, Germany, Italy, Poland, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03419897. Inclusion in this directory is not an endorsement.